Minimum Effective Volume of 0.375% Bupivacaine in Interscalene Brachial Plexus Block
Information source: Federal University of São Paulo
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Shoulder Surgery
Intervention: Bupivacaine 0,375% (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Federal University of São Paulo
Summary
The use of ultrasound in regional anesthesia enables reduction in the local anesthetic
volume. The present study aimed to determine the minimum effective volume of 0. 375%
bupivacaine with epinephrine for interscalene brachial plexus block for shoulder surgery.
Following approval by the Research Ethics Committee, patients with a physical condition of I
or II according to the American Society of Anesthesiologists, between 21 and 65 years old
and subjected to elective surgery of the shoulder and interscalene brachial plexus block
will be recruited. The volume of the anesthetic will be determined using a step-up/step-down
method and based on the outcome of the preceding block. Positive or negative block results
in a 1mL reduction or increase in volume, respectively. The success of the block is defined
as the presence of motor block in two muscle groups and the absence of thermal and pain
sensations in the necessary dermatomes within 30 minutes of the injection. Diaphragmatic
paralysis, pulmonary function and analgesia will be quantified at 30 minutes, 4 and 6 hours.
Data will undergo statistical analysis in order to determine minimum effective volume of
0. 375% bupivacaine and, secondarily, the maximum volume that maintains the diaphragmatic
function, evaluate diaphragm paralysis and its influence in pulmonary function.
Clinical Details
Official title: Minimum Effective Volume of 0.375% Bupivacaine in Ultrasound- and Nerve Stimulator-guided Interscalene Brachial Plexus Block for Shoulder Surgery
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Minimum effective volume of 0,375% bupivacaine
Secondary outcome: Maximum 0,375% bupivacaine volume that maintains the diaphragmatic functionPulmonary function Diaphragmatic Function
Eligibility
Minimum age: 21 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age between 21 and 65 years
- Candidates for an elective surgical intervention on the shoulder with indication for
anesthesia via brachial plexus block
- Physical condition of I or II according to the American Society of Anesthesiologists
- Body mass index up to 35 kg. m-2
Exclusion Criteria:
- Chronic obstructive pulmonary disease
- Cognitive impairment or active psychiatric condition
- Infection at the site of the puncture for the block
- Coagulopathy
- Bupivacaine allergy
Locations and Contacts
Federal University of Sao Paulo, Sao Paulo 04024-002, Brazil; Recruiting Luiz Fernando Saldanha de Almeida, MD, Email: luizfsa@gmail.com Marcelo Vaz Perez, MD PhD, Email: marcelovazperez@gmail.com Marcelo V Perez, MD PhD, Sub-Investigator
Additional Information
Starting date: August 2012
Last updated: August 16, 2012
|